
September 4, 2008 : TxCell appoints Marc Beer as Chairman of the Supervisory Board. March 5, 2008 : TxCell completes a 10.5 million second round and initiates its first clinical trial. 

September 16-18, 2009
BioPharma AmericaSan Francisco, USA More information here
September 23-25, 2009
Eurobio Lille, France San Francisco, USA
More information here

|
New approach in immunosuppressive strategies Txcell strategy is to develop investigational products in a new class of autologous cellular immunotherapies that are uniquely designed to regulate the patient's own immune system. Autologous cellular immunotherapies hold promise because they may provide patients meaningful clinical benefits with low toxicity. TxCell develops innovative treatments for Crohn's (phase I/IIa) and Rheumatoid Arthritis patients (pre-clinical stage). TxCell is a spin-off from the French Medical Research Institute (INSERM) . |
|
|
|